ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Thermo Fisher Scientific has agreed to purchase the specialty diagnostic firm Binding Site for $2.6 billion. The company, which is currently owned by the private equity firm Nordic Capital, makes assays and instruments for diagnosing and measuring immune disorders and blood cancers. Its flagship product serves people with multiple myeloma. Binding Site says it expects income of $220 million in 2022 and employs 1,100 workers worldwide. The firms expect the deal to close in the first half of 2023.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X